CJC-1295 with DAC

CJC-1295 with DAC is a synthetic long-acting analogue of growth hormone–releasing hormone (GHRH) designed to stimulate sustained secretion of endogenous growth hormone from the pituitary gland. The “DAC” (Drug Affinity Complex) modification allows it to bind to albumin in the bloodstream, significantly extending its half-life and producing prolonged elevations in growth hormone and IGF-1 levels compared to shorter-acting GHRH analogs.

In scientific research, CJC-1295 with DAC is studied for its effects on growth hormone axis regulation, including potential influences on protein synthesis, lipolysis, tissue repair, and overall metabolic function. Because of its extended activity, it is also used to examine long-duration hormonal signaling and its downstream effects on body composition and recovery processes.

CJC-1295 with DAC is primarily used in laboratory and preclinical research to better understand endocrine modulation, sustained growth hormone release, and the physiological impact of elevated IGF-1 signaling over time.